Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

SELL
$27.11 - $35.17 $125,193 - $162,415
-4,618 Reduced 20.26%
18,174 $619,000
Q4 2023

Feb 14, 2024

BUY
$22.72 - $29.68 $517,834 - $676,466
22,792 New
22,792 $659,000
Q4 2022

Feb 14, 2023

BUY
$31.09 - $37.88 $182,436 - $222,279
5,868 New
5,868 $209,000
Q1 2021

May 17, 2021

SELL
$24.15 - $31.45 $998,771 - $1.3 Million
-41,357 Closed
0 $0
Q4 2020

Feb 16, 2021

BUY
$17.7 - $25.81 $544,186 - $793,528
30,745 Added 289.72%
41,357 $1.04 Million
Q3 2020

Nov 16, 2020

SELL
$20.2 - $25.05 $198,263 - $245,865
-9,815 Reduced 48.05%
10,612 $221,000
Q2 2020

Aug 17, 2020

BUY
$17.09 - $24.89 $349,097 - $508,428
20,427 New
20,427 $485,000
Q1 2020

May 15, 2020

SELL
$14.45 - $24.69 $2.34 Million - $4 Million
-162,156 Closed
0 $0
Q4 2019

Feb 14, 2020

BUY
$19.93 - $29.13 $3.23 Million - $4.72 Million
162,156 New
162,156 $3.85 Million
Q2 2019

Aug 14, 2019

SELL
$29.96 - $38.87 $1.19 Million - $1.54 Million
-39,731 Closed
0 $0
Q1 2019

May 15, 2019

SELL
$32.77 - $41.99 $179,120 - $229,517
-5,466 Reduced 12.09%
39,731 $1.39 Million
Q4 2018

Feb 14, 2019

BUY
$30.84 - $49.51 $1.39 Million - $2.24 Million
45,197 New
45,197 $1.5 Million
Q3 2018

Nov 01, 2018

SELL
$42.7 - $56.55 $2.34 Million - $3.1 Million
-54,903 Closed
0 $0
Q2 2018

Aug 03, 2018

SELL
$44.1 - $59.85 $574,137 - $779,187
-13,019 Reduced 19.17%
54,903 $3.29 Million
Q1 2018

May 07, 2018

BUY
$37.15 - $46.9 $897,358 - $1.13 Million
24,155 Added 55.19%
67,922 $3.11 Million
Q4 2017

Feb 01, 2018

SELL
$36.4 - $42.6 $215,597 - $252,319
-5,923 Reduced 11.92%
43,767 $1.74 Million
Q3 2017

Nov 13, 2017

BUY
$36.75 - $49.65 $1.83 Million - $2.47 Million
49,690
49,690 $1.99 Million

Others Institutions Holding SUPN

About SUPERNUS PHARMACEUTICALS, INC.


  • Ticker SUPN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 53,495,300
  • Market Cap $1.71B
  • Description
  • Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...
More about SUPN
Track This Portfolio

Track Engineers Gate Manager LP Portfolio

Follow Engineers Gate Manager LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Engineers Gate Manager LP, based on Form 13F filings with the SEC.

News

Stay updated on Engineers Gate Manager LP with notifications on news.